Please use this identifier to cite or link to this item:
Title: Effect of Calcium-Channel Blocker Therapy on Radial Artery Grafts After Coronary�?Bypass�?Surgery.
Austin Authors: Gaudino, Mario;Benedetto, Umberto;Fremes, Stephen E;Hare, David L ;Hayward, Philip;Moat, Neil;Moscarelli, Marco;Di Franco, Antonino;Nasso, Giuseppe;Peric, Miodrag;Petrovic, Ivana;Puskas, John D;Speziale, Giuseppe;Yoo, Kyung Jong;Girardi, Leonard N;Taggart, David P
Affiliation: Department of Cardiothoracic Surgery, Cornell Medicine, New York, New York
Bristol Heart Institute, Bristol, United Kingdom
Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
University of Melbourne, Melbourne, Victoria, Australia
Austin Health
Royal Brompton & Harefield Trust, London, United Kingdom
Anthea Hospital, Bari, Italy
Dedinje Cardiovascular Institute and Belgrade University School of Medicine, Belgrade, Serbia
Icahn School of Medicine at Mount Sinai, New York, New York
Yonsei University College of Medicine, Seoul, Korea
University of Oxford, Oxford, United Kingdom
Issue Date: 14-May-2019
Publication information: Journal of the American College of Cardiology 2019; 73(18): 2299-2306
Abstract: Few studies have evaluated the effect of chronic calcium-channel blocker therapy (CCB) on the angiographic and clinical outcome of radial artery (RA) grafts used for coronary bypass surgery. The purpose of this study was to evaluate if CCB influences midterm clinical and angiographic outcomes of RA grafts. Patient-level data of 6 angiographic randomized trials evaluating RA graft status at midterm follow-up were joined in this observational analysis. Cox regression and propensity score methods were used to evaluate the effect of CCB on the incidence of a composite of major adverse cardiac events (MACE) (death, myocardial infarction, and repeat revascularization) and graft occlusion. The study population included 732 patients (502 on CCB). The median clinical follow-up was 60 months. The cumulative incidence of MACE at 36, 72, and 108 months was 3.7% vs. 9.3%, 13.4% vs. 17.6%, and 16.8% vs. 20.5% in the CCB and no CCB groups, respectively (log-rank p = 0.003). Protocol-driven angiographic follow-up was available in 243 patients in the CCB group and 200 in the no CCB group. The median angiographic follow-up was 55 months. The cumulative incidence of RA occlusion at 36, 72, and 108 months was 0.9% vs. 8.6%, 9.6% vs. 21.4%, and 14.3% vs. 38.9% in the CCB and no CCB groups, respectively (log-rank p < 0.001). After controlling for known confounding, CCB therapy was found to be consistently associated with a significantly lower risk of MACE (multivariate Cox hazard ratio: 0.52; 95% confidence interval: 0.31 to 0.89; p = 0.02) and RA graft occlusion (multivariate Cox hazard ratio: 0.20; 95% confidence interval: 0.08 to 0.49; p < 0.001). In patients with RA grafts CCB is associated with significantly better midterm clinical and angiographic RA outcomes.
DOI: 10.1016/j.jacc.2019.02.054
Journal: Journal of the American College of Cardiology
PubMed URL: 31072574
Type: Journal Article
Subjects: CABG
calcium-channel blocker
radial artery
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 12, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.